Immune Pharmaceuticals, Inc. (IMNP.ST)

Stockholm - Stockholm Delayed Price. Currency in SEK
3.00-0.08 (-2.60%)
At close: 11:29 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close3.08
Bid2.99 x
Ask3.00 x
Day's Range2.90 - 3.07
52wk Range1.82 - 16.80
1y Target EstN/A
Market Cap237.54M
P/E Ratio (ttm)-3.68
Avg Vol (3m)766,543
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • Zacks Small Cap Research4 months ago

    IMNP: Phase 2 Clinical Trials of Bertilimumab Ongoing; Subsidiary to Develop Immunooncology Products.…

    By David Bautz, PhD NASDAQ:IMNP Financial Update   On March 30, 2016, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the fourth quarter and full year 2015 and provided a business update. ...

  • Zacks Small Cap Research9 months ago

    IMNP: Clinical Sites to Open for BP Trial in the U.S.…

    On November 11, 2015, Immune Pharmaceuticals, Inc. (IMNP) announced financial results for the third quarter of 2015 and provided a business update. This acceptance will enable the company to expand recruitment for the ongoing Phase 2 clinical trial to three planned clinical trial sites in the U.S., including Mount Sinai School of Medicine in New York City.

  • Zacks Small Cap Research10 months ago

    IMNP: Large Market Opportunity for Bertilimumab in the Treatment of Inflammatory Bowel Diseases

    The company’s lead asset, bertilimumab, is a monoclonal antibody that targets eotaxin-1, and is currently in Phase 2 clinical trials for the treatment of bullous pemphigoid (BP) and ulcerative colitis (UC). Additional future indications for bertilimumab include Crohn’s disease (CD), severe asthma, nonalcoholic steatohepatitis (NASH), and atopic dermatitis. For the purposes of this update, we will focus on the development of bertilimumab in the treatment of inflammatory bowel diseases (IBD), which include UC and CD, and examine the current treatment options as well as the market potential for bertilimumab in these indications.